Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

Video

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Related Videos
Scott Kopetz, MD, PhD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
Scott Kopetz, MD, PhD, FACP
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Pashtoon Murtaza Kasi, MD, MS
Related Content
Awny Farajallah, MD, of Takeda

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
Heinz-Josef Lenz, MD, University of Southern California Norris Comprehensive Cancer Center

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024
Article
Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology

August 1st 2022
Podcast
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
Eric S. Christenson, MD, assistant professor, oncology, Johns Hopkins Medicine

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024
Article